{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:02:02Z","timestamp":1794258122836,"version":"4.9.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["4021861"],"award-info":[{"award-number":["4021861"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106694","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:54:21Z","timestamp":1755845661000},"page":"106694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Mesenchymal stem cells in clinical trials for multiple sclerosis: A systematic literature review and review of clinical trials"],"prefix":"10.1016","volume":"103","author":[{"given":"Mohammad Ali","family":"Nahayati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Ghavidel Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Hassanisabzevar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Baniasadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Forouzanfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1679-1068","authenticated-orcid":false,"given":"Ehsan","family":"Saburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106694_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144534","article-title":"Different osteogenic differentiation potential of mesenchymal stem cells on three different polymeric substrates","volume":"740","author":"Abazari","year":"2020","journal-title":"Gene"},{"issue":"34","key":"10.1016\/j.msard.2025.106694_bib0030","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021646","article-title":"The effect of stem cell therapy and comprehensive physical therapy in motor and non-motor symptoms in patients with multiple sclerosis: a comparative study","volume":"99","author":"Alghwiri","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.msard.2025.106694_bib0006","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-030-55035-6_6","article-title":"Immunoregulatory effects of tolerogenic probiotics in multiple sclerosis","volume":"1286","author":"Atabati","year":"2021","journal-title":"Adv. Exp. Med. Biol"},{"issue":"4","key":"10.1016\/j.msard.2025.106694_bib0045","article-title":"Serum neurofilament light chain concentration in a phase 1\/2 trial of autologous mesenchymal stem cell transplantation","volume":"5","author":"Baldassari","year":"2019","journal-title":"Multiple Scler. J. \u2013 Experiment., Translation. Clinic."},{"key":"10.1016\/j.msard.2025.106694_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103779","article-title":"Mesenchymal stem cell therapy and cognition in MS: preliminary findings from a phase II clinical trial","volume":"61","author":"Berard","year":"2022","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2025.106694_bib0052","first-page":"10","article-title":"Mesenchymal stem cell therapy for multiple sclerosis","author":"Bonab","year":"2005","journal-title":"Int. J. Hematol. Oncol. Stem. Cell Res"},{"key":"10.1016\/j.msard.2025.106694_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibtech.2025.04.009","article-title":"Large-scale manufacturing of human gallbladder epithelial cell products and derived hepatocytes via a chemically defined approach","author":"Chen","year":"2025","journal-title":"Trend. Biotechnol"},{"issue":"4","key":"10.1016\/j.msard.2025.106694_bib0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"24","author":"Cohen","year":"2018","journal-title":"Mult. Scler"},{"issue":"4","key":"10.1016\/j.msard.2025.106694_bib0038","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"24","author":"Cohen","year":"2018","journal-title":"Multiple Scler. J"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/13524585221122156","article-title":"Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis","volume":"29","author":"Cohen","year":"2023","journal-title":"Multiple Sclerosis. J"},{"issue":"2","key":"10.1016\/j.msard.2025.106694_bib0041","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study","volume":"11","author":"Connick","year":"2012","journal-title":"Lancet. Neurol"},{"issue":"11","key":"10.1016\/j.msard.2025.106694_bib0037","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/cns.12759","article-title":"Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy","volume":"23","author":"Dahbour","year":"2017","journal-title":"CNS Neurosci. Ther"},{"issue":"2","key":"10.1016\/j.msard.2025.106694_bib0032","article-title":"Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"5","author":"Feng","year":"2019","journal-title":"Multiple Scler. J. \u2013 Experiment., Translati. Clinic."},{"issue":"5","key":"10.1016\/j.msard.2025.106694_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195891","article-title":"Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I\/II safety and feasibility study","volume":"13","author":"Fern\u00e1ndez","year":"2018","journal-title":"Plos One"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0054","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12031-012-9805-6","article-title":"Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS","volume":"48","author":"Fisher-Shoval","year":"2012","journal-title":"J. Mol. Neurosci"},{"issue":"3","key":"10.1016\/j.msard.2025.106694_bib0001","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2217\/nmt.15.6","article-title":"Stem cell therapy in multiple sclerosis: a future perspective","volume":"5","author":"Harris","year":"2015","journal-title":"Neurodegener. Dis. Manag"},{"issue":"12","key":"10.1016\/j.msard.2025.106694_bib0039","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jcyt.2016.08.007","article-title":"Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis","volume":"18","author":"Harris","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.msard.2025.106694_bib0036","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ebiom.2018.02.002","article-title":"Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis","volume":"29","author":"Harris","year":"2018","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0028","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000928","article-title":"Mesenchymal stem cell-derived neural progenitors in progressive MS: two-year follow-up of a phase I study","volume":"8","author":"Harris","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0023","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13287-024-03765-6","article-title":"Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial","volume":"15","author":"Harris","year":"2024","journal-title":"Stem. Cell Res. Ther"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55094-0","article-title":"Neuromorphic-enabled video-activated cell sorting","volume":"15","author":"He","year":"2024","journal-title":"Nat. Commun"},{"issue":"12","key":"10.1016\/j.msard.2025.106694_bib0007","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1080\/10286020.2024.2371040","article-title":"Mechanisms and therapeutic potential of chinonin in nervous system diseases","volume":"26","author":"Hui","year":"2024","journal-title":"J. Asian Nat. Prod. Res"},{"issue":"12","key":"10.1016\/j.msard.2025.106694_bib0033","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3390\/jcm8122102","article-title":"Short and long term clinical and immunologic follow up after bone marrow mesenchymal stromal cell therapy in progressive multiple sclerosis\u2014a phase I study","volume":"8","author":"Iacobaeus","year":"2019","journal-title":"J. Clin. Med"},{"issue":"1-2","key":"10.1016\/j.msard.2025.106694_bib0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2007.05.005","article-title":"Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological\/neurodegenerative diseases","volume":"265","author":"Karussis","year":"2008","journal-title":"J. Neurol. Sci"},{"issue":"10","key":"10.1016\/j.msard.2025.106694_bib0042","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.msard.2025.106694_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155635","article-title":"Curcumin-primed olfactory mucosa-derived mesenchymal stem cells mitigate cerebral ischemia\/reperfusion injury-induced neuronal PANoptosis by modulating microglial polarization","volume":"129","author":"Lan","year":"2024","journal-title":"Phytomedicine"},{"issue":"Suppl 1","key":"10.1016\/j.msard.2025.106694_bib0040","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.3727\/096368914X685005","article-title":"The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis","volume":"23","author":"Li","year":"2014","journal-title":"Cell Transplant"},{"issue":"12","key":"10.1016\/j.msard.2025.106694_bib0015","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1038\/s41375-024-02423-3","article-title":"Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.msard.2025.106694_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2024.04.021","article-title":"Modified lentiviral globin gene therapy for pediatric beta(0)\/beta(0) transfusion-dependent beta-thalassemia: a single-center, single-arm pilot trial","volume":"31","author":"Li","year":"2024","journal-title":"Cell Stem. Cell"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0018","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12967-025-06298-5","article-title":"Proteomic analysis reveals chromatin remodeling as a potential therapeutical target in neuroblastoma","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med"},{"issue":"12","key":"10.1016\/j.msard.2025.106694_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113936","article-title":"Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis","volume":"9","author":"Llufriu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2025.106694_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00967","article-title":"IV\/IT hUC-MSCs infusion in RRMS and NMO: A 10-year follow-up study","volume":"11","author":"Lu","year":"2020","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.msard.2025.106694_bib0003","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult. Scler. Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0046","first-page":"212","article-title":"Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis","volume":"10","author":"Meng","year":"2018","journal-title":"Am. J. Transl. Res"},{"issue":"3","key":"10.1016\/j.msard.2025.106694_bib0050","first-page":"155","article-title":"FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy","volume":"10","author":"Mohajeri","year":"2011","journal-title":"Iran J. Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0051","first-page":"50","article-title":"Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study","volume":"4","author":"Mohyeddin Bonab","year":"2007","journal-title":"Iran J. Immunol"},{"issue":"6","key":"10.1016\/j.msard.2025.106694_bib0049","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/157488812804484648","article-title":"Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study","volume":"7","author":"Mohyeddin Bonab","year":"2012","journal-title":"Curr. Stem. Cell Res. Ther"},{"issue":"4","key":"10.1016\/j.msard.2025.106694_bib0048","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.arcmed.2013.03.007","article-title":"Evaluation of cytokines in multiple sclerosis patients treated with mesenchymal stem cells","volume":"44","author":"Mohyeddin Bonab","year":"2013","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.msard.2025.106694_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104895","article-title":"Intravenous transplantation of bone marrow-derived mesenchymal stromal cells in patients with multiple sclerosis, a phase I\/IIa, double blind, randomized controlled study","volume":"78","author":"Nabavi","year":"2023","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"2","key":"10.1016\/j.msard.2025.106694_bib0022","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4252\/wjsc.v6.i2.195","article-title":"Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility","volume":"6","author":"Nagamura-Inoue","year":"2014","journal-title":"World J. Stem. Cells"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0058","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13104-023-06316-z","article-title":"Responsiveness of persian 12-item multiple sclerosis walking scale: a replication study","volume":"16","author":"Naghdi","year":"2023","journal-title":"BMC Res. Notes"},{"issue":"6","key":"10.1016\/j.msard.2025.106694_bib0004","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr. Opin. Neurol"},{"key":"10.1016\/j.msard.2025.106694_bib0043","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4067\/S0717-95022022000100143","article-title":"Efficiency and safety of umbilical cord mesenchymal stromal\/stem cells in multiple sclerosis combined treatment","volume":"40","author":"Petriv","year":"2022","journal-title":"Int. J. Morphol"},{"issue":"12","key":"10.1016\/j.msard.2025.106694_bib0027","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0056","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/stcltm\/szab017","article-title":"Effects of mesenchymal stem cell transplantation on cerebrospinal fluid biomarkers in progressive multiple sclerosis","volume":"11","author":"Petrou","year":"2022","journal-title":"Stem. Cells Transl. Med"},{"key":"10.1016\/j.msard.2025.106694_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578613","article-title":"Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01)","volume":"403","author":"Petrou","year":"2025","journal-title":"J. Neuroimmunol"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s13287-022-03189-0","article-title":"Mesenchymal stem cell aggregation mediated by integrin \u03b14\/VCAM-1 after intrathecal transplantation in MCAO rats","volume":"13","author":"Ran","year":"2022","journal-title":"Stem. Cell Res. Ther"},{"key":"10.1016\/j.msard.2025.106694_bib0053","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1479-5876-7-29","article-title":"Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis","volume":"7","author":"Riordan","year":"2009","journal-title":"J. Transl. Med"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12967-018-1433-7","article-title":"Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis","volume":"16","author":"Riordan","year":"2018","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.msard.2025.106694_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.145471","article-title":"The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19","volume":"777","author":"Saburi","year":"2021","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.msard.2025.106694_bib0047","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5812\/archneurosci.13687","article-title":"Intrathecal mesenchymal stem cell therapy in multiple sclerosis: a follow-up study for five years after injection","volume":"1","author":"Sahraian","year":"2014","journal-title":"Arch Neurosci"},{"issue":"2","key":"10.1016\/j.msard.2025.106694_bib0034","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08820139.2018.1504301","article-title":"Therapeutic use of intrathecal mesenchymal stem cells in patients with Multiple sclerosis: a pilot study with booster injection","volume":"48","author":"Sahraian","year":"2019","journal-title":"Immunol. Invest"},{"issue":"2","key":"10.1016\/j.msard.2025.106694_bib0057","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08820139.2018.1504301","article-title":"Therapeutic use of intrathecal mesenchymal stem cells in patients with Multiple sclerosis: a pilot study with booster injection","volume":"48","author":"Sahraian","year":"2019","journal-title":"Immunol. Invest"},{"key":"10.1016\/j.msard.2025.106694_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1566670","article-title":"Optimal sca-1-based procedure for purifying mouse adipose-derived mesenchymal stem cells with enhanced proliferative and differentiation potential","volume":"13","author":"Tao","year":"2025","journal-title":"Front Cell Dev. Biol"},{"issue":"2","key":"10.1016\/j.msard.2025.106694_bib0014","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/iub.2154","article-title":"Unfolded protein response-mediated modulation of mesenchymal stem cells","volume":"72","author":"Tavasolian","year":"2020","journal-title":"Iubmb Life"},{"key":"10.1016\/j.msard.2025.106694_bib0044","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clinph.2022.01.125","article-title":"Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis","volume":"136","author":"Tremblay","year":"2022","journal-title":"Clinic. Neurophysiol"},{"issue":"11","key":"10.1016\/j.msard.2025.106694_bib0029","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1474-4422(21)00301-X","article-title":"Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial","volume":"20","author":"Uccelli","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0017","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1038\/srep08362","article-title":"Quantitative analysis of injury-induced anterior subcapsular cataract in the mouse: a model of lens epithelial cells proliferation and epithelial-mesenchymal transition","volume":"5","author":"Xiao","year":"2015","journal-title":"Sci. Rep"},{"issue":"1-2","key":"10.1016\/j.msard.2025.106694_bib0009","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","article-title":"Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study","volume":"227","author":"Yamout","year":"2010","journal-title":"J. Neuroimmunol"},{"issue":"9","key":"10.1016\/j.msard.2025.106694_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2024.06.007","article-title":"Nynrin preserves hematopoietic stem cell function by inhibiting the mitochondrial permeability transition pore opening","volume":"31","author":"Zhou","year":"2024","journal-title":"Cell Stem. Cell"},{"issue":"1","key":"10.1016\/j.msard.2025.106694_bib0016","first-page":"48","article-title":"TGF-beta1 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson's disease models and patients","volume":"11","author":"Zhuo","year":"2024","journal-title":"Mil Med. Res"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:18:58Z","timestamp":1774999138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":61,"alternative-id":["S2211034825004365"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106694","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesenchymal stem cells in clinical trials for multiple sclerosis: A systematic literature review and review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106694"}}